Sir: The recent discovery of impurities found in the heart-drug “Valsartan”, as well as its subsequent recalling by DRAP has been a disturbing headline for patients diagnosed with blood-pressure and heart diseases who had been prescribed this drug. According to a 2017 WHO (World Health Organisation) report, Pakistan is ranked as possessing some of the highest rates of cardiovascular diseases in the world. In light of this revelation, patients who have already been administered Valsartan have been advised to continue with their prescribed dosage but purchase medicines approved by DRAP and Drug Regulatory Unit of Punjab. This news is sending waves of anxiety, given its discovery of carrying a carcinogenic impurity. Recalled by the European Medicines Agency (EMA) in July 2018, the composition of Valsartan has been found carrying N-Nitrosodimethylamine (a carcinogen); hence it has been abruptly halted from distribution. One may ponder over the plight of patients who have no alternative means available with regards to this drug, as well as the long-term damage insinuated. It is of utmost importance that national drug administrations in Pakistan work closely with their global counterparts to shine light on such discoveries before stamping their approval for sales. Given the high levels of trust placed on them by the public, it is vital that this trust not be compromised. NUZAIR A VIRANI Karachi Published in Daily Times, August 10th 2018.